CDKN2A and urinary bladder carcinoma: Several research studies have shown promoter hypermethylation and silencing of other TSGs in renal cancer; VHL (von Hippel–Lindau) [35] in bladder cancer; the cell cycle regulator CDKN2 A/p16 [36]; and in colon cancer, the mismatch repair gene hMLH1 [37].